Literature DB >> 11956071

Forced expression of NESH suppresses motility and metastatic dissemination of malignant cells.

Yasukatu Ichigotani1, Shouichi Yokozaki, Yoshihide Fukuda, Michinari Hamaguchi, Satoru Matsuda.   

Abstract

To characterize the function of a novel Src homology 3 (SH3) adapter protein termed NESH, we have established transfectants stably expressing NESH. We observed that every clone of NESH transfectants caused a marked reduction in motility, although the clones exhibited no significant differences in intrinsic cell growth compared with the control cells in vitro. The NESH transfectants also exhibited significant reduction in tumor metastatic potential in vivo. We found that NESH expression is frequently lost in invasive cancer cell lines despite its ubiquitous expression in normal tissues. The SH3 domain of NESH seems to interact with p21-activated kinase (PAK), which is involved in regulation of cell motility. Furthermore, a significant decrease in PAK phosphorylation at (402)Thr was found in NESH transfectants. Taken together, these results suggest that NESH inhibits ectopic metastasis of tumor cells as well as cell migration through interaction with intracellular molecules such as PAK that are essential for cell motility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956071

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression.

Authors:  Janete M Cerutti; Rosana Delcelo; Marcelo João Amadei; Claudia Nakabashi; Rui M B Maciel; Bercedis Peterson; Jennifer Shoemaker; Gregory J Riggins
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  NESH protein expression switches to the adverse effect of imatinib mesylate.

Authors:  Satoru Matsuda; Yasukatu Ichigotani; Naoko Okumura; Hitomi Yoshida; Yuka Kajiya; Yasuko Kitagishi; Naoki Shirafuji
Journal:  Mol Oncol       Date:  2008-03-20       Impact factor: 6.603

3.  Cancer-associated loss of TARSH gene expression in human primary lung cancer.

Authors:  Kunihiko Terauchi; Junichi Shimada; Natsuko Uekawa; Takeshi Yaoi; Mitsuo Maruyama; Shinji Fushiki
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-04       Impact factor: 4.553

4.  Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease.

Authors:  Jun-Ichi Satoh; Yoshihiro Kino; Motoaki Yanaizu; Youhei Tosaki; Kenji Sakai; Tsuyoshi Ishida; Yuko Saito
Journal:  Intractable Rare Dis Res       Date:  2017-11

5.  Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion.

Authors:  Flavia R M Latini; Jefferson P Hemerly; Gisele Oler; Gregory J Riggins; Janete M Cerutti
Journal:  Endocr Relat Cancer       Date:  2008-06-17       Impact factor: 5.678

6.  ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence.

Authors:  Flavia R M Latini; Jefferson P Hemerly; Beatriz C G Freitas; Gisele Oler; Gregory J Riggins; Janete M Cerutti
Journal:  BMC Cancer       Date:  2011-01-11       Impact factor: 4.430

7.  NESH regulates dendritic spine morphology and synapse formation.

Authors:  Jeomil Bae; Bong Hwan Sung; In Ha Cho; Seon-Myung Kim; Woo Keun Song
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

8.  F-actin-dependent regulation of NESH dynamics in rat hippocampal neurons.

Authors:  Jeomil Bae; Bong Hwan Sung; In Ha Cho; Woo Keun Song
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

9.  The NESH/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex.

Authors:  Saki Sekino; Yuriko Kashiwagi; Hitoshi Kanazawa; Kazuki Takada; Takashi Baba; Seiichi Sato; Hiroki Inoue; Masaki Kojima; Katsuko Tani
Journal:  Cell Commun Signal       Date:  2015-10-01       Impact factor: 5.712

10.  A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer.

Authors:  Macarena Perán; Elena López-Ruiz; María Ángel García; Shorena Nadaraia-Hoke; Ralf Brandt; Juan A Marchal; Julian Kenyon
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.